JAIDS Journal of Acquired Immune Deficiency Syndromes · 2007 · 51 citations · 26 references
Public HealthPharmacotherapyClinical PharmacologyHiv ControlHiv PreventionAntiretroviral TherapyAntiviral TherapyHiv EpidemiologyAntiviral Therapy DiscontinuationCd4 Cell Count MonitoringCross-sectional EpidemiologyHighly Active Antiretroviral TherapyHiv Antiretroviral TherapyUnstructured Clinical Interviews
BACKGROUND: Data on discontinuation and modification of highly active antiretroviral therapy (HAART) are scarce among sub-Saharan African populations. We sought to estimate the prevalence and to identify factors associated with these phenomena in our resource-limited setting. METHODS: Patients were recruited into this cross-sectional study from 2 treatment centers in Kampala, Uganda. Discontinuation and modification were assessed by self-report using semistructured quantitative and unstructured qualitative interviews. Discontinuation was defined as the simultaneous stopping of all antiretrovirals for at least 1 month, and modification as the changing of at least 1 antiretroviral used in an initial HAART regimen. Factors independently associated with each outcome were assessed using multivariate logistic regression. RESULTS: Of 686 subjects evaluated, 94 (13.7%) had ever discontinued therapy, whereas 175 (25.5%) had ever modified their regimen. The median CD4 count was 175 (interquartile range: 66-297) cells/microL. Factors associated with discontinuation were HAART experience before starting the current regimen (odds ratio [OR] = 3.70, 95% confidence interval [CI]: 2.13 to 6.25), use of alternative medicines (OR = 2.18, 95% CI: 1.06 to 4.47), hospitalization (OR = 2.36, 95% CI: 1.32 to 4.20), and 1 year or less on HAART (OR = 11.11, 95% CI: 5.00 to 25.00). Modification was associated with more than 3 months' duration on HAART (OR = 3.13, 95% CI: 1.16 to 8.33) and being unmarried (OR = 1.64, 95% CI: 1.02 to 2.70). CONCLUSIONS: The proportions of discontinuation and modification of antiretroviral therapy (ART) observed in our resource-poor setting pose a challenge to the limited treatment options presently available. Drug cost as a major reason for discontinuation of HAART has major implications for ART programs that charge fees in resource-limited settings.
26
Antonella d’Arminio Monforte, Alessandro Cozzi‐Lepri, Giovanni Rezza et al. · AIDS · 2000 · 560 citations
Gonzague Jourdain, Nicole Ngo‐Giang‐Huong, Chureeratana Bowonwatanuwong et al. · New England Journal of Medicine · 2004 · 444 citations · Full text